Treatment of Lambert-Eaton Syndrome With 3, 4-Diaminopyridine
Patients with clinically-confirmed LEMS will receive 3, 4 DAP by mouth in slowly increasing
doses. Treatment will begin with 5 mg, three times a day and will increase by 50% every two
weeks to 10-15 mg, three to six times a day, as clinically needed, and if tolerated.
Patients will be monitored for strength and side effects via routine out-patient clinic
visits at initial intervals of 1 month, increasing to intervals of 6 months as permitted.
Subjects will be asked to temporarily stop study drug to determine if there is a return of
symptoms and need for continued treatment with 3, 4 DAP. Results of treatment and adverse
events will be reported to the FDA. Treatment will be continued indefinitely if a good
clinical response is achieved and side effects are tolerable.
David Richman, MD
University of California, Davis
United States: Food and Drug Administration
|University of California, Davis||Sacramento, California 95818|